{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:22:15Z","timestamp":1794352935261,"version":"4.9.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57805-7","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T08:46:37Z","timestamp":1781426797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Ludovica","family":"Cella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Fasulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Uleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Piccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Mallia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Saita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Hurle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Casale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lughezzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2 Maria","family":"Buffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Lazzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Paciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"57805_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein, J. M. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 Amendment. J. Urol. 211, 533\u2013538. https:\/\/doi.org\/10.1097\/JU.0000000000003846 (2024).","journal-title":"J. Urol."},{"key":"57805_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4274\/haseki.galenos.2026.44265","volume":"64","author":"M Beyatli","year":"2026","unstructured":"Beyatli, M. et al. Flexible cystoscopy patient experience: Comparative effects of irrigation techniques on comfort and satisfaction. Med. Bull. Haseki. 64, 18\u201325. https:\/\/doi.org\/10.4274\/haseki.galenos.2026.44265 (2026).","journal-title":"Med. Bull. Haseki"},{"key":"57805_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.juro.2017.09.141","volume":"199","author":"E Wallace","year":"2018","unstructured":"Wallace, E. et al. Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection. J. Urol. 199, 655\u2013662. https:\/\/doi.org\/10.1016\/j.juro.2017.09.141 (2018).","journal-title":"J. Urol."},{"key":"57805_CR4","unstructured":"Cepheid Xpert Bladder Cancer Detection\u2014IFU (CE-IVD). n.d. (2023)."},{"key":"57805_CR5","unstructured":"Cepheid Xpert Bladder Cancer Monitor\u2014product page. n.d. (2025)."},{"key":"57805_CR6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.euo.2025.04.020","volume":"8","author":"BJ Schmitz-Dr\u00e4ger","year":"2025","unstructured":"Schmitz-Dr\u00e4ger, B. J. et al. Results of the prospective randomized urofollow trial comparing marker-guided versus cystoscopy-based surveillance in patients with low\/intermediate-risk bladder cancer. Eur. Urol. Oncol. 8, 1041\u20131049. https:\/\/doi.org\/10.1016\/j.euo.2025.04.020 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"57805_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.euros.2024.09.001","volume":"71","author":"F Sordelli","year":"2025","unstructured":"Sordelli, F. et al. Xpert bladder cancer detection in emergency setting assessment (XESA Project): A prospective, single-centre trial. Eur. Urol. Open. Sci. 71, 172\u2013179. https:\/\/doi.org\/10.1016\/j.euros.2024.09.001 (2025).","journal-title":"Eur. Urol. Open. Sci."},{"key":"57805_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","volume":"88","author":"T Dreyer","year":"2025","unstructured":"Dreyer, T. et al. Use of the Xpert bladder cancer monitor urinary biomarker test for guiding cystoscopy in high-grade non-muscle-invasive bladder cancer: results from the randomized controlled DaBlaCa-15 Trial. Eur. Urol. 88, 23\u201330. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.018 (2025).","journal-title":"Eur. Urol."},{"key":"57805_CR9","doi-asserted-by":"publisher","unstructured":"Macchi, A. et al. mRNA-based urine test performance in high and very-high risk non-muscle-invasive bladder cancer patients undergoing contextual endoscopic follow-up (VERNAL: Vesical tumor early monitoring: mrna-based follow-up). Clin. Genitourin. Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2025.102333 (2025).","DOI":"10.1016\/j.clgc.2025.102333"},{"key":"57805_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/bju.15194","volume":"127","author":"P Gontero","year":"2021","unstructured":"Gontero, P. et al. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non\u2010muscle\u2010invasive bladder cancer: a blinded prospective multicentric study. BJU Int. 127, 198\u2013204. https:\/\/doi.org\/10.1111\/bju.15194 (2021).","journal-title":"BJU Int."},{"key":"57805_CR11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.euf.2022.02.006","volume":"8","author":"M Roupr\u00eat","year":"2022","unstructured":"Roupr\u00eat, M. et al. Reducing the frequency of follow-up cystoscopy in low-grade pTa non-muscle-invasive bladder cancer using the ADXBLADDER biomarker. Eur. Urol. Focus. 8, 1643\u20131649. https:\/\/doi.org\/10.1016\/j.euf.2022.02.006 (2022).","journal-title":"Eur. Urol. Focus"},{"key":"57805_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","volume":"1","author":"JA Witjes","year":"2018","unstructured":"Witjes, J. A. et al. Performance of the bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: Results of a multicenter, prospective, blinded clinical trial. Eur. Urol. Oncol. 1, 307\u2013313. https:\/\/doi.org\/10.1016\/j.euo.2018.06.011 (2018).","journal-title":"Eur. Urol. Oncol."},{"key":"57805_CR13","unstructured":"Julian Higgins, J., Thomas, T., Li, M. & Page Vivian Welch. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane; n.d. (2023)."},{"key":"57805_CR14","doi-asserted-by":"publisher","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","DOI":"10.1136\/bmj.n71"},{"key":"57805_CR15","doi-asserted-by":"publisher","unstructured":"Stroup, D. F. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008. https:\/\/doi.org\/10.1001\/jama.283.15.2008 (2000).","DOI":"10.1001\/jama.283.15.2008"},{"key":"57805_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.eururo.2025.07.021","volume":"88","author":"AJ Vickers","year":"2025","unstructured":"Vickers, A. J. et al. Guidelines for meta-analyses and systematic reviews in urology. Eur. Urol. 88, 421\u2013426. https:\/\/doi.org\/10.1016\/j.eururo.2025.07.021 (2025).","journal-title":"Eur. Urol."},{"key":"57805_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","volume":"73","author":"T Knoll","year":"2018","unstructured":"Knoll, T. et al. Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology. Eur. Urol. 73, 290\u2013300. https:\/\/doi.org\/10.1016\/j.eururo.2017.08.016 (2018).","journal-title":"Eur. Urol."},{"key":"57805_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting, P. F. et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155, 529\u2013536. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009 (2011).","journal-title":"Ann. Intern. Med."},{"key":"57805_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","volume":"58","author":"JB Reitsma","year":"2005","unstructured":"Reitsma, J. B. et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J. Clin. Epidemiol. 58, 982\u2013990. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.02.022 (2005).","journal-title":"J. Clin. Epidemiol."},{"key":"57805_CR20","doi-asserted-by":"publisher","first-page":"e2019007","DOI":"10.4178\/epih.e2019007","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim, S. R., Kim, S-J. & Lee, J. Diagnostic test accuracy: application and practice using R software. Epidemiol. Health. 41, e2019007. https:\/\/doi.org\/10.4178\/epih.e2019007 (2019).","journal-title":"Epidemiol. Health"},{"key":"57805_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","volume":"75","author":"M Assel","year":"2019","unstructured":"Assel, M. et al. Guidelines for reporting of statistics for clinical research in urology. Eur. Urol. 75, 358\u2013367. https:\/\/doi.org\/10.1016\/j.eururo.2018.12.014 (2019).","journal-title":"Eur. Urol."},{"key":"57805_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2019.02.003","volume":"111","author":"HJ Sch\u00fcnemann","year":"2019","unstructured":"Sch\u00fcnemann, H. J. et al. GRADE guidelines: 22. The GRADE approach for tests and strategies\u2014from test accuracy to patient-important outcomes and recommendations. J. Clin. Epidemiol. 111, 69\u201382. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.02.003 (2019).","journal-title":"J. Clin. Epidemiol."},{"key":"57805_CR23","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","volume":"58","author":"JJ Deeks","year":"2005","unstructured":"Deeks, J. J., Macaskill, P. & Irwig, L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J. Clin. Epidemiol. 58, 882\u2013893. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.01.016 (2005).","journal-title":"J. Clin. Epidemiol."},{"key":"57805_CR24","doi-asserted-by":"publisher","unstructured":"Breyer, J. et al. Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial). Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-023-42088-z (2023).","DOI":"10.1038\/s41598-023-42088-z"},{"key":"57805_CR25","doi-asserted-by":"publisher","unstructured":"Singer, G. et al. The role of new technologies in the diagnosis and surveillance of non-muscle invasive bladder carcinoma: A prospective, double-blinded, monocentric study of the XPERT\u00a9 bladder cancer monitor and narrow band Imaging\u00a9 cystoscopy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14030618 (2022).","DOI":"10.3390\/cancers14030618"},{"key":"57805_CR26","doi-asserted-by":"publisher","first-page":"437e11","DOI":"10.1016\/j.urolonc.2021.02.009","volume":"39","author":"AA Elsawy","year":"2021","unstructured":"Elsawy, A. A., Awadalla, A., Abdullateef, M., Ahmed, A. E. & Abol-Enein, H. Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker. Urol. Oncol. Semin. Orig. Investig. 39, 437e11. https:\/\/doi.org\/10.1016\/j.urolonc.2021.02.009 (2021).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"57805_CR27","doi-asserted-by":"publisher","unstructured":"Lozano, F. et al. Xpert bladder cancer monitor for the early detection of non-muscle invasive bladder cancer recurrences: Could cystoscopy be substituted? Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15143683 (2023).","DOI":"10.3390\/cancers15143683"},{"key":"57805_CR28","doi-asserted-by":"publisher","unstructured":"Kavcic, N., Peric, I., Zagorac, A. & Kokalj Vokac, N. Clinical evaluation of two non-invasive genetic tests for detection and monitoring of urothelial carcinoma: Validation of UroVysion and Xpert bladder cancer detection test. Front. Genet. https:\/\/doi.org\/10.3389\/fgene.2022.839598 (2022).","DOI":"10.3389\/fgene.2022.839598"},{"key":"57805_CR29","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00345-019-03002-3","volume":"38","author":"R Hurle","year":"2020","unstructured":"Hurle, R. et al. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. World J. Urol. 38, 2215\u20132220. https:\/\/doi.org\/10.1007\/s00345-019-03002-3 (2020).","journal-title":"World J. Urol."},{"key":"57805_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3233\/BLC-200318","volume":"6","author":"AA Elsawy","year":"2020","unstructured":"Elsawy, A. A. et al. Diagnostic performance of novel urine-based mRNA tests (Xpert and urinary metabolomics markers assay) for bladder cancer detection in patients with hematuria. Bladder Cancer. 6, 319\u2013328. https:\/\/doi.org\/10.3233\/BLC-200318 (2020).","journal-title":"Bladder Cancer"},{"key":"57805_CR31","doi-asserted-by":"publisher","unstructured":"D\u2019Elia, C. et al. Diagnostic value of Xpert\u00ae Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update. Ther. Adv. Urol. https:\/\/doi.org\/10.1177\/1756287221997183 (2021).","DOI":"10.1177\/1756287221997183"},{"key":"57805_CR32","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s00345-021-03629-1","volume":"39","author":"G Cancel-Tassin","year":"2021","unstructured":"Cancel-Tassin, G. et al. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. World J. Urol. 39, 3329\u20133335. https:\/\/doi.org\/10.1007\/s00345-021-03629-1 (2021).","journal-title":"World J. Urol."},{"key":"57805_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.euo.2020.09.001","volume":"4","author":"FJP van Valenberg","year":"2021","unstructured":"van Valenberg, F. J. P. et al. Validation of an mRNA-based urine test for the detection of bladder cancer in patients with haematuria. Eur. Urol. Oncol. 4, 93\u2013101. https:\/\/doi.org\/10.1016\/j.euo.2020.09.001 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"57805_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cncy.22246","volume":"128","author":"E Trenti","year":"2020","unstructured":"Trenti, E. et al. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer. Cancer Cytopathol. 128, 341\u2013347. https:\/\/doi.org\/10.1002\/cncy.22246 (2020).","journal-title":"Cancer Cytopathol."},{"key":"57805_CR35","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2478\/raon-2020-0072","volume":"55","author":"T Smrkolj","year":"2020","unstructured":"Smrkolj, T., Cegovnik Primozic, U., Fabjan, T., Sterpin, S. & Osredkar, J. The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors. Radiol. Oncol. 55, 196\u2013202. https:\/\/doi.org\/10.2478\/raon-2020-0072 (2020).","journal-title":"Radiol. Oncol."},{"key":"57805_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bju.14019","volume":"121","author":"R Pichler","year":"2018","unstructured":"Pichler, R. et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 121, 29\u201337. https:\/\/doi.org\/10.1111\/bju.14019 (2018).","journal-title":"BJU Int."},{"key":"57805_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/bju.16389","volume":"134","author":"M Haas","year":"2024","unstructured":"Haas, M. et al. Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert\u00ae BC Monitor. BJU Int. 134, 755\u2013762. https:\/\/doi.org\/10.1111\/bju.16389 (2024).","journal-title":"BJU Int."},{"key":"57805_CR38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/bju.15418","volume":"128","author":"B Cowan","year":"2021","unstructured":"Cowan, B. et al. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer. BJU Int. 128, 713\u2013721. https:\/\/doi.org\/10.1111\/bju.15418 (2021).","journal-title":"BJU Int."},{"key":"57805_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.euros.2024.10.016","volume":"70","author":"S Abuhasanein","year":"2024","unstructured":"Abuhasanein, S., Radmann, J., Jahnson, S. & Kj\u00f6lhede, H. Diagnostic performance of GeneXpert BC as a triage test for patients presenting with macroscopic hematuria suspicious for urinary bladder cancer: A multicenter prospective case-control study. Eur. Urol. Open. Sci. 70, 158\u2013166. https:\/\/doi.org\/10.1016\/j.euros.2024.10.016 (2024).","journal-title":"Eur. Urol. Open. Sci."},{"key":"57805_CR40","doi-asserted-by":"publisher","first-page":"77e9","DOI":"10.1016\/j.urolonc.2020.07.013","volume":"39","author":"AA Elsawy","year":"2021","unstructured":"Elsawy, A. A., Awadalla, A., Elsayed, A., Abdullateef, M. & Abol-Enein, H. Prospective validation of clinical usefulness of a novel mRNA-based urine test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in non muscle invasive bladder cancer. Urol. Oncol. Semin. Orig. Investig. 39, 77e9. https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.013 (2021).","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"57805_CR41","doi-asserted-by":"publisher","unstructured":"D\u2019Elia, C. et al. Xpert\u00ae bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results. Ther. Adv. Urol. https:\/\/doi.org\/10.1177\/17562872221090320 (2022).","DOI":"10.1177\/17562872221090320"},{"key":"57805_CR42","unstructured":"Kassem, H. A. et al. Recurrence monitoring in Egyptian Bladder Cancer patients using effective and predictive urinary molecular biomarkers: A pilot study Recurrence monitoring in Egyptian Bladder Cancer\u2026 Neemat M. 55. (2021)."},{"key":"57805_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/BLC-230089","volume":"10","author":"C Schmitz-Dr\u00e4ger","year":"2024","unstructured":"Schmitz-Dr\u00e4ger, C. et al. Potential of an mRNA-based urine assay (Xpert\u00ae Bladder Cancer Detection1) in hematuria patients\u2014results from a cohort study. Bladder Cancer. 10, 25\u201333. https:\/\/doi.org\/10.3233\/BLC-230089 (2024).","journal-title":"Bladder Cancer"},{"key":"57805_CR44","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00345-023-04350-x","volume":"41","author":"S Pycha","year":"2023","unstructured":"Pycha, S. et al. Diagnostic value of Xpert\u00ae BC Detection, Bladder Epicheck\u00ae, Urovysion\u00ae FISH and cytology in the detection of upper urinary tract urothelial carcinoma. World J. Urol. 41, 1323\u20131328. https:\/\/doi.org\/10.1007\/s00345-023-04350-x (2023).","journal-title":"World J. Urol."},{"key":"57805_CR45","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/23523735241304348","volume":"10","author":"N Fleshner","year":"2024","unstructured":"Fleshner, N. et al. North American study and meta-analysis evaluating performance of Bladder EpiCheck \u00ae, a FDA cleared test, in non-muscle invasive bladder cancer recurrence. Bladder Cancer. 10, 278\u2013289. https:\/\/doi.org\/10.1177\/23523735241304348 (2024).","journal-title":"Bladder Cancer"},{"key":"57805_CR46","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.3390\/ijms21186542","volume":"21","author":"M Mancini","year":"2020","unstructured":"Mancini, M., Righetto, M., Zumerle, S., Montopoli, M. & Zattoni, F. The bladder EpiCheck test as a non-invasive tool based on the identification of DNA methylation in bladder cancer cells in the urine: a review of published evidence. Int. J. Mol. Sci. 21, 6542. https:\/\/doi.org\/10.3390\/ijms21186542 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"57805_CR47","doi-asserted-by":"publisher","first-page":"105e11","DOI":"10.1016\/j.urolonc.2021.11.001","volume":"40","author":"G Cochetti","year":"2022","unstructured":"Cochetti, G. et al. Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial. Urol. Oncol. Semin. Orig. Investig.. 40, 105e11. https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.001 (2022).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"57805_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/JU.0000000000004335","volume":"213","author":"P Ramos","year":"2025","unstructured":"Ramos, P. et al. Uromonitor: Clinical validation and performance assessment of a urinary biomarker within the surveillance of patients with nonmuscle-invasive bladder cancer. J. Urol. 213, 304\u2013312. https:\/\/doi.org\/10.1097\/JU.0000000000004335 (2025).","journal-title":"J. Urol."},{"key":"57805_CR49","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/cancers16040753","volume":"16","author":"AP Kravchuk","year":"2024","unstructured":"Kravchuk, A. P. et al. urine-based biomarker test Uromonitor\u00ae in the detection and disease monitoring of non-muscle-invasive bladder cancer\u2014A systematic review and meta-analysis of diagnostic test performance. Cancers (Basel). 16, 753. https:\/\/doi.org\/10.3390\/cancers16040753 (2024).","journal-title":"Cancers (Basel)"},{"key":"57805_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40487-018-0059-5","volume":"6","author":"T Lough","year":"2018","unstructured":"Lough, T. et al. Clinical utility of cxbladder monitor for patients with a history of urothelial carcinoma: A physician-patient real-world clinical data analysis. Oncol. Ther. 6, 73\u201385. https:\/\/doi.org\/10.1007\/s40487-018-0059-5 (2018).","journal-title":"Oncol. Ther."},{"key":"57805_CR51","doi-asserted-by":"publisher","unstructured":"Li, K. D. et al. Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urol. Oncol. Semin. Orig. Investig. 41, 326.e1\u2013326.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2023.01.009 (2023).","DOI":"10.1016\/j.urolonc.2023.01.009"},{"key":"57805_CR52","doi-asserted-by":"publisher","first-page":"131e17","DOI":"10.1016\/j.urolonc.2020.06.018","volume":"39","author":"F Pierconti","year":"2021","unstructured":"Pierconti, F. et al. The combination cytology\/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence? Urol. Oncol. Semin. Orig. Investig. 39, 131e17. https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.018 (2021).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"57805_CR53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cncy.22657","volume":"131","author":"F Pierconti","year":"2023","unstructured":"Pierconti, F. et al. DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group. Cancer Cytopathol. 131, 158\u2013164. https:\/\/doi.org\/10.1002\/cncy.22657 (2023).","journal-title":"Cancer Cytopathol."},{"key":"57805_CR54","doi-asserted-by":"publisher","first-page":"12489","DOI":"10.3390\/ijms241512489","volume":"24","author":"V Fiorentino","year":"2023","unstructured":"Fiorentino, V. et al. Bladder Epicheck test: A novel tool to support urothelial carcinoma diagnosis in urine samples. Int. J. Mol. Sci. 24, 12489. https:\/\/doi.org\/10.3390\/ijms241512489 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"57805_CR55","doi-asserted-by":"publisher","first-page":"108e19","DOI":"10.1016\/j.urolonc.2021.11.013","volume":"40","author":"F Pierconti","year":"2022","unstructured":"Pierconti, F. et al. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma. Urol. Oncol. Semin. Orig. Investig. 40, 108e19. https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.013 (2022).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"57805_CR56","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.3390\/biomedicines11123288","volume":"11","author":"F Pierconti","year":"2023","unstructured":"Pierconti, F. et al. Methylation analysis of urinary sample in non-muscle-invasive bladder carcinoma: Frequency and management of invalid result. Biomedicines 11, 3288. https:\/\/doi.org\/10.3390\/biomedicines11123288 (2023).","journal-title":"Biomedicines"},{"key":"57805_CR57","doi-asserted-by":"publisher","unstructured":"Pepe, L. et al. The simultaneous use of bladder Epicheck\u00ae and urinary cytology can improve the sensitivity and specificity of diagnostic follow-up of urothelial lesions: Up-to-date data from a multi-institutional Cohort Dis. 12, 219. https:\/\/doi.org\/10.3390\/diseases12090219 (2024).","DOI":"10.3390\/diseases12090219"},{"key":"57805_CR58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.humpath.2021.09.007","volume":"118","author":"F Pierconti","year":"2021","unstructured":"Pierconti, F. et al. Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples. Hum. Pathol. 118, 42\u201348. https:\/\/doi.org\/10.1016\/j.humpath.2021.09.007 (2021).","journal-title":"Hum. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57805-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:08:25Z","timestamp":1788134905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57805-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57805"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57805-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27184"}}